KR20230122100A - Cdk2 억제제의 고체 형태 - Google Patents
Cdk2 억제제의 고체 형태 Download PDFInfo
- Publication number
- KR20230122100A KR20230122100A KR1020237024476A KR20237024476A KR20230122100A KR 20230122100 A KR20230122100 A KR 20230122100A KR 1020237024476 A KR1020237024476 A KR 1020237024476A KR 20237024476 A KR20237024476 A KR 20237024476A KR 20230122100 A KR20230122100 A KR 20230122100A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- ppm
- crystalline
- values
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cereal-Derived Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130530P | 2020-12-24 | 2020-12-24 | |
| US63/130,530 | 2020-12-24 | ||
| PCT/IB2021/062082 WO2022137106A1 (en) | 2020-12-24 | 2021-12-21 | Solid forms of a cdk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230122100A true KR20230122100A (ko) | 2023-08-22 |
Family
ID=79283019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237024476A Pending KR20230122100A (ko) | 2020-12-24 | 2021-12-21 | Cdk2 억제제의 고체 형태 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076287A1 (https=) |
| EP (1) | EP4267563A1 (https=) |
| JP (1) | JP2024503235A (https=) |
| KR (1) | KR20230122100A (https=) |
| CN (1) | CN116723837A (https=) |
| AU (1) | AU2021404974B2 (https=) |
| CA (1) | CA3206153A1 (https=) |
| MX (1) | MX2023007699A (https=) |
| TW (1) | TWI823213B (https=) |
| WO (1) | WO2022137106A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| US20250195475A1 (en) * | 2022-01-27 | 2025-06-19 | InventisBio Co., Ltd. | Cdk2 inhibitor and preparation method and use thereof |
| WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
| WO2025191482A1 (en) | 2024-03-15 | 2025-09-18 | Pfizer Inc. | Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| IL284589B2 (en) | 2019-01-31 | 2025-10-01 | Pfizer | 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity |
-
2021
- 2021-12-21 WO PCT/IB2021/062082 patent/WO2022137106A1/en not_active Ceased
- 2021-12-21 US US18/268,959 patent/US20240076287A1/en active Pending
- 2021-12-21 KR KR1020237024476A patent/KR20230122100A/ko active Pending
- 2021-12-21 CN CN202180086069.9A patent/CN116723837A/zh active Pending
- 2021-12-21 MX MX2023007699A patent/MX2023007699A/es unknown
- 2021-12-21 CA CA3206153A patent/CA3206153A1/en active Pending
- 2021-12-21 AU AU2021404974A patent/AU2021404974B2/en active Active
- 2021-12-21 EP EP21839682.8A patent/EP4267563A1/en active Pending
- 2021-12-21 JP JP2023537491A patent/JP2024503235A/ja active Pending
- 2021-12-23 TW TW110148386A patent/TWI823213B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024503235A (ja) | 2024-01-25 |
| CA3206153A1 (en) | 2022-06-30 |
| MX2023007699A (es) | 2023-07-10 |
| AU2021404974A9 (en) | 2025-04-10 |
| WO2022137106A1 (en) | 2022-06-30 |
| CN116723837A (zh) | 2023-09-08 |
| US20240076287A1 (en) | 2024-03-07 |
| TWI823213B (zh) | 2023-11-21 |
| AU2021404974B2 (en) | 2024-11-28 |
| TW202233606A (zh) | 2022-09-01 |
| EP4267563A1 (en) | 2023-11-01 |
| AU2021404974A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7291839B2 (ja) | 固体形態のｃｄｋ４阻害薬 | |
| AU2021404974B2 (en) | Solid forms of a cdk2 inhibitor | |
| US20240000783A1 (en) | Combination therapy | |
| JP2025540560A (ja) | Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩 | |
| RU2850825C1 (ru) | Твердые формы ингибитора cdk2 | |
| RU2856216C1 (ru) | Твердые формы ингибитора cdk4 | |
| CA3195063C (en) | Solid forms of the cdk4 inhibitor pf-07220060 | |
| HK40096368A (zh) | Cdk2抑制剂的固体形式 | |
| BR112023004713B1 (pt) | Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica | |
| HK40087859A (zh) | Cdk4抑制剂的固体形式 | |
| HK40096012A (zh) | 组合疗法 | |
| HK40125945A (zh) | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 | |
| HK1233924A1 (en) | Derivatives of cephalosporin for treating cancer | |
| HK1233924B (en) | Derivatives of cephalosporin for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |